Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02825212|
Recruitment Status : Completed
First Posted : July 7, 2016
Last Update Posted : August 6, 2019
10 patients with chronic genotype 1 HCV infection and mixed cryoglobulinemia will be treated with Ledipasvir/Sofosbuvir 90mg/400 mg FDC once daily for 12 weeks (naïve subjects or non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with cirrhosis).
The researchers anticipate that approximately 20% of subjects may have cirrhosis.
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis C Cryoglobulinemia||Drug: Harvoni||Phase 2 Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|
|Study Start Date :||February 2016|
|Actual Primary Completion Date :||July 19, 2019|
|Actual Study Completion Date :||July 19, 2019|
90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.
12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
- Sustained Virologic Response (SVR) [ Time Frame: up to 24 weeks after treatment ]proportion of subjects who attain SVR
- Response in patients with mixed cryoglobulinemia (MC) [ Time Frame: up to 24 weeks after treatment ]Response to medication in patients with MC categorized as either complete response vs partial response
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02825212
|United States, New York|
|Icahn School of Medicine at Mount Sinai|
|New York, New York, United States, 10029|
|Principal Investigator:||Peter Gorevic, MD||Icahn School of Medicine at Mount Sinai|